The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Public ClinicalTrials.gov record NCT06319872. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
The Effects of Disulfiram on Visual Acuity in Patients With Retinal Degeneration
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram on the vision of patients with retinal degeneration who are being treated with the drug in the management of their concurrent alcohol use disorder.
Study identification
- NCT ID
- NCT06319872
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 15 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 18, 2025
- Primary completion
- May 18, 2029
- Completion
- May 18, 2029
- Last update posted
- Sep 28, 2025
2025 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Flaum Eye Institute, University of Rochester Medical Center | Rochester | New York | 14642 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated Age-Related Macular Degeneration trials
Other public records listing Age-Related Macular Degeneration. Sorted by last update posted; newest first. Not a recommendation.
- NCT06662162: Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration Recruiting
- NCT06237127: Effects of Goji vs. Fiber on Macular Degeneration Recruiting
- NCT05300724: An Observational Study of the Progression of Intermediate Age-Related Macular Degeneration Active, not recruiting
- NCT07605468: Feasibility Study of a Remote Behavioral Dietary Intervention in Patients With Early to Intermediate AMD: Glucose Lowering for Vision Extension Not yet recruiting
- NCT07594236: Phase 1 Study of C.001 in Retinal Degeneration Recruiting
- NCT06593405: The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06319872, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2025 · Synced Aug 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06319872 live on ClinicalTrials.gov.